Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Valent

Showing results (601-610 of 662) with videos related to

Pageof 67
Sort By:
Blood|January 29, 2021
Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosisMarcelo A S Toledo, Malrun Gatz, Stephanie Sontag, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM ConsortiumPolina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
The Journal of Clinical Investigation|May 9, 2017
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsMargaret Nieborowska-Skorska, Katherine Sullivan, Yashodhara Dasgupta, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.
British Journal of Haematology|September 22, 2025
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR studyCelalettin Ustun, Mei-Jie Zhang, Andrew Peterson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 24, 2021
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical ReviewTheo Gülen, Cem Akin, Patrizia Bonadonna, et al.
International Journal of Molecular Sciences|April 20, 2017
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational StudyAntonio M Almeida, Thomas Prebet, Raphael Itzykson, et al.
Pageof 67

Showing results (601-610 of 662) with videos related to

Sort By:
Pageof 67
Blood|January 29, 2021
Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosisMarcelo A S Toledo, Malrun Gatz, Stephanie Sontag, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Refined Treatment Response Criteria for Indolent Systemic Mastocytosis Proposed by the ECNM-AIM ConsortiumPolina Pyatilova, Cem Akin, Iván Alvarez-Twose, et al.
The Journal of Allergy and Clinical Immunology. in Practice|August 12, 2023
The Normal Range of Baseline Tryptase Should Be 1 to 15 ng/mL and Covers Healthy Individuals With HαTPeter Valent, Gregor Hoermann, Patrizia Bonadonna, et al.
The Journal of Clinical Investigation|May 9, 2017
Gene expression and mutation-guided synthetic lethality eradicates proliferating and quiescent leukemia cellsMargaret Nieborowska-Skorska, Katherine Sullivan, Yashodhara Dasgupta, et al.
The Journal of Allergy and Clinical Immunology. in Practice|May 27, 2022
Global Classification of Mast Cell Activation Disorders: An ICD-10-CM-Adjusted Proposal of the ECNM-AIM ConsortiumPeter Valent, Karin Hartmann, Patrizia Bonadonna, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 20, 2022
Proposed European Competence Network on Mastocytosis-American Initiative in Mast Cell Diseases (ECNM-AIM) Response Criteria in Advanced Systemic MastocytosisJason Gotlib, Juliana Schwaab, William Shomali, et al.
British Journal of Haematology|September 22, 2025
Allogeneic haematopoietic cell transplantation in advanced systemic mastocytosis in the new era: A CIBMTR studyCelalettin Ustun, Mei-Jie Zhang, Andrew Peterson, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 8, 2021
COVID-19 Vaccination in Mastocytosis: Recommendations of the European Competence Network on Mastocytosis (ECNM) and American Initiative in Mast Cell Diseases (AIM)Patrizia Bonadonna, Knut Brockow, Marek Niedoszytko, et al.
The Journal of Allergy and Clinical Immunology. in Practice|June 24, 2021
Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical ReviewTheo Gülen, Cem Akin, Patrizia Bonadonna, et al.
International Journal of Molecular Sciences|April 20, 2017
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational StudyAntonio M Almeida, Thomas Prebet, Raphael Itzykson, et al.
Pageof 67